[{"id":"beb344ab-95cf-420e-8ccd-b61bc4f7a537","acronym":"","url":"https://clinicaltrials.gov/study/NCT07097363","created_at":"2025-08-02T14:05:17.045Z","updated_at":"2025-08-02T14:05:17.045Z","phase":"Phase 2","brief_title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT07097363","lead_sponsor":"University of Washington","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 05/31/2030","primary_completion_date":" 05/31/2030","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2025-07-31"},{"id":"4325258d-71bf-4423-9ce6-1de5375d6cd1","acronym":"NCI-2020-09704","url":"https://clinicaltrials.gov/study/NCT04640779","created_at":"2025-02-25T12:27:49.994Z","updated_at":"2025-02-25T12:27:49.994Z","phase":"Phase 1","brief_title":"Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT04640779 - NCI-2020-09704","lead_sponsor":"Mayo Clinic","biomarkers":" XPO1","pipe":"","alterations":" ","tags":["XPO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 02/08/2021","start_date":" 02/08/2021","primary_txt":" Primary completion: 08/15/2026","primary_completion_date":" 08/15/2026","study_txt":" Completion: 08/15/2027","study_completion_date":" 08/15/2027","last_update_posted":"2025-02-24"},{"id":"d0e8c003-1353-4bf0-ae65-13236586de27","acronym":"AIM-NIVO","url":"https://clinicaltrials.gov/study/NCT03816345","created_at":"2021-01-18T18:51:20.043Z","updated_at":"2025-02-25T13:39:45.299Z","phase":"Phase 1","brief_title":"Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer","source_id_and_acronym":"NCT03816345 - AIM-NIVO","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • IL2","pipe":"","alterations":" ","tags":["MSI • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 07/16/2019","start_date":" 07/16/2019","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-02-21"},{"id":"da3b2b09-ed01-4312-97c2-dda82f0fd6ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04799275","created_at":"2021-03-16T18:52:53.431Z","updated_at":"2025-02-25T13:53:42.140Z","phase":"Phase 2/3","brief_title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04799275","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • CD4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 422","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-02-20"},{"id":"59d4a003-e862-4682-ad7b-ffa3cb7e3e25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190174","created_at":"2021-01-18T15:43:45.733Z","updated_at":"2025-02-25T14:15:01.560Z","phase":"Phase 1/2","brief_title":"Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers","source_id_and_acronym":"NCT03190174","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/24/2017","start_date":" 08/24/2017","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/02/2021","study_completion_date":" 12/02/2021","last_update_posted":"2025-02-17"},{"id":"2bded2d4-47b6-42ef-85b2-a3d47668df11","acronym":"BELINDA","url":"https://clinicaltrials.gov/study/NCT03570892","created_at":"2021-01-18T17:34:21.137Z","updated_at":"2025-02-25T14:39:57.185Z","phase":"Phase 3","brief_title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03570892 - BELINDA","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 331","initiation":"Initiation: 05/07/2019","start_date":" 05/07/2019","primary_txt":" Primary completion: 05/06/2021","primary_completion_date":" 05/06/2021","study_txt":" Completion: 02/14/2026","study_completion_date":" 02/14/2026","last_update_posted":"2025-02-14"},{"id":"39b387f7-5892-466f-8ae2-7eceb33eb0d5","acronym":"CTL-DP 01","url":"https://clinicaltrials.gov/study/NCT04180059","created_at":"2021-01-29T07:20:01.998Z","updated_at":"2025-02-25T15:18:23.580Z","phase":"Phase 1","brief_title":"Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT04180059 - CTL-DP 01","lead_sponsor":"Nantes University Hospital","biomarkers":" CD4 • HLA-DPB1","pipe":"","alterations":" ","tags":["CD4 • HLA-DPB1"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 02/09/2020","start_date":" 02/09/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-12"},{"id":"23df8c55-37d1-4d81-9a8c-51e5c6811bf0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03983850","created_at":"2021-01-18T19:35:37.156Z","updated_at":"2025-02-25T15:26:05.857Z","phase":"Phase 1/2","brief_title":"Optimizing PTCy Dose and Timing","source_id_and_acronym":"NCT03983850","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • PTEN • IGH • FBXW7","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS • PTEN • IGH • FBXW7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 07/09/2019","start_date":" 07/09/2019","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-11"},{"id":"c0f4d14f-2257-447f-847c-ebe3a10d55e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01087294","created_at":"2023-05-20T02:04:59.343Z","updated_at":"2025-02-25T15:32:08.685Z","phase":"Phase 1","brief_title":"Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT01087294","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 08/04/2010","start_date":" 08/04/2010","primary_txt":" Primary completion: 03/08/2024","primary_completion_date":" 03/08/2024","study_txt":" Completion: 04/02/2024","study_completion_date":" 04/02/2024","last_update_posted":"2025-02-11"},{"id":"3a5c5d6a-237c-4943-9f23-41234e0aa377","acronym":"","url":"https://clinicaltrials.gov/study/NCT03755804","created_at":"2021-01-18T18:27:48.805Z","updated_at":"2025-02-25T16:37:17.115Z","phase":"Phase 2","brief_title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","source_id_and_acronym":"NCT03755804","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • dacarbazine • bendamustine • bleomycin • vinblastine • Neupogen (filgrastim) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-07"},{"id":"6fa362b2-89c2-4884-87bd-ac57c53e5ca0","acronym":"E4412","url":"https://clinicaltrials.gov/study/NCT01896999","created_at":"2021-01-29T07:05:03.634Z","updated_at":"2025-02-25T16:36:17.132Z","phase":"Phase 1/2","brief_title":"Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT01896999 - E4412","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-1 • CD4 • LGALS1 • ICOS","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • CD4 • LGALS1 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Adcetris (brentuximab vedotin) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 03/07/2014","start_date":" 03/07/2014","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-06"},{"id":"aa4d2f71-0b09-413a-abc9-1d8702d772bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065866","created_at":"2021-10-04T12:53:00.645Z","updated_at":"2025-02-25T16:45:37.143Z","phase":"Phase 1","brief_title":"Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy","source_id_and_acronym":"NCT05065866","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Copiktra (duvelisib) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 11/18/2021","start_date":" 11/18/2021","primary_txt":" Primary completion: 01/02/2024","primary_completion_date":" 01/02/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-06"},{"id":"7f3a4417-d9e1-41f2-85e6-183300a2b151","acronym":"NCI-2017-01311","url":"https://clinicaltrials.gov/study/NCT03246906","created_at":"2021-01-18T16:02:34.370Z","updated_at":"2025-02-25T16:44:11.978Z","phase":"Phase 2","brief_title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","source_id_and_acronym":"NCT03246906 - NCI-2017-01311","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/11/2017","start_date":" 09/11/2017","primary_txt":" Primary completion: 05/03/2025","primary_completion_date":" 05/03/2025","study_txt":" Completion: 05/03/2025","study_completion_date":" 05/03/2025","last_update_posted":"2025-02-05"},{"id":"fac97f31-c725-4a50-bd5b-feddf6e7b709","acronym":"CARCD30","url":"https://clinicaltrials.gov/study/NCT01192464","created_at":"2021-01-18T04:46:17.774Z","updated_at":"2025-02-25T16:51:03.913Z","phase":"Phase 1","brief_title":"EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma","source_id_and_acronym":"NCT01192464 - CARCD30","lead_sponsor":"Baylor College of Medicine","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 05/10/2011","start_date":" 05/10/2011","primary_txt":" Primary completion: 05/29/2012","primary_completion_date":" 05/29/2012","study_txt":" Completion: 10/01/2033","study_completion_date":" 10/01/2033","last_update_posted":"2025-02-04"},{"id":"42d2a0f4-bf25-41be-9b41-ecad4c959f5d","acronym":"CK-301-101","url":"https://clinicaltrials.gov/study/NCT03212404","created_at":"2021-01-18T15:50:41.447Z","updated_at":"2025-02-25T16:59:32.024Z","phase":"Phase 1","brief_title":"Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers","source_id_and_acronym":"NCT03212404 - CK-301-101","lead_sponsor":"Checkpoint Therapeutics, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Unloxcyt (cosibelimab-ipdl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 11/18/2021","primary_completion_date":" 11/18/2021","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"d95c33d6-345e-4cbd-b542-479174b36f3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05797233","created_at":"2023-04-04T16:03:56.139Z","updated_at":"2025-02-25T17:02:29.485Z","phase":"Phase 1","brief_title":"Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies","source_id_and_acronym":"NCT05797233","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" MET expression","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 08/28/2023","start_date":" 08/28/2023","primary_txt":" Primary completion: 12/30/2028","primary_completion_date":" 12/30/2028","study_txt":" Completion: 12/30/2029","study_completion_date":" 12/30/2029","last_update_posted":"2025-02-03"},{"id":"e7d829bd-de22-4969-85f4-ae3c9695ba2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06090864","created_at":"2025-02-25T17:02:58.123Z","updated_at":"2025-02-25T17:02:58.123Z","phase":"Phase 1/2","brief_title":"ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells","source_id_and_acronym":"NCT06090864","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8 • CCR4","pipe":"","alterations":" ","tags":["TNFRSF8 • CCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • TT11 • ATLCAR.CD30.CCR4 cells"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/25/2024","start_date":" 04/25/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2031","study_completion_date":" 07/01/2031","last_update_posted":"2025-02-03"},{"id":"1bb717ea-4a5e-4f29-ac5a-fee115e523c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03179930","created_at":"2021-01-18T15:40:48.245Z","updated_at":"2025-02-25T16:06:23.103Z","phase":"Phase 2","brief_title":"Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas","source_id_and_acronym":"NCT03179930","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CTLA4","pipe":"","alterations":" ","tags":["CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 06/07/2017","start_date":" 06/07/2017","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-01-24"},{"id":"8e68b197-bc4f-4479-9ecd-61cd7d26dc27","acronym":"MEPI-AGE","url":"https://clinicaltrials.gov/study/NCT06761274","created_at":"2025-02-26T07:31:58.859Z","updated_at":"2025-02-26T07:31:58.859Z","phase":"","brief_title":"Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma","source_id_and_acronym":"NCT06761274 - MEPI-AGE","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" KLRG1 • B3GAT1","pipe":"","alterations":" ","tags":["KLRG1 • B3GAT1"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-01-07"},{"id":"688f7919-86e0-4ff0-8b2a-5d36de39804f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06487624","created_at":"2025-02-26T10:01:41.524Z","updated_at":"2025-02-26T10:01:41.524Z","phase":"Phase 1","brief_title":"An Engineered Sirpα Fused to Anti-Pd-L1 and Tgf-β Fusion Protein (HCB301) in Subjects with Selected Advanced Tumors","source_id_and_acronym":"NCT06487624","lead_sponsor":"FBD Biologics Limited","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/30/2025","start_date":" 01/30/2025","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-12-11"},{"id":"00f2945d-93f1-4243-9713-50b181253dce","acronym":"NCI-2018-02699","url":"https://clinicaltrials.gov/study/NCT03749018","created_at":"2021-01-18T18:23:00.454Z","updated_at":"2025-02-25T14:27:50.683Z","phase":"Phase 2","brief_title":"Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT03749018 - NCI-2018-02699","lead_sponsor":"David Bond, MD","biomarkers":" PD-L1 • BCL2 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • BCL2 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/02/2019","start_date":" 01/02/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-11-04"},{"id":"ea7acd25-7f5f-485b-920f-36c4074db856","acronym":"","url":"https://clinicaltrials.gov/study/NCT06617286","created_at":"2025-02-26T10:28:12.676Z","updated_at":"2025-02-26T10:28:12.676Z","phase":"Phase 1/2","brief_title":"CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma","source_id_and_acronym":"NCT06617286","lead_sponsor":"New York Medical College","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/31/2039","primary_completion_date":" 12/31/2039","study_txt":" Completion: 12/31/2040","study_completion_date":" 12/31/2040","last_update_posted":"2024-10-18"},{"id":"14051df5-1544-41fb-8d54-4063aac116ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04847050","created_at":"2025-02-26T12:21:42.752Z","updated_at":"2025-02-26T12:21:42.752Z","phase":"Phase 2","brief_title":"A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy","source_id_and_acronym":"NCT04847050","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/28/2021","start_date":" 04/28/2021","primary_txt":" Primary completion: 05/25/2023","primary_completion_date":" 05/25/2023","study_txt":" Completion: 05/25/2023","study_completion_date":" 05/25/2023","last_update_posted":"2024-08-27"},{"id":"c3e37946-e4b9-4544-a60c-995c415bbbe7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06563778","created_at":"2025-02-26T10:28:05.577Z","updated_at":"2025-02-26T10:28:05.577Z","phase":"Phase 2","brief_title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","source_id_and_acronym":"NCT06563778","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • Adcetris (brentuximab vedotin) • Epidaza (chidamide) • bendamustine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-08-21"}]